Seng H. is responsible for drug discovery, process development and clinical supply as well as clinical biomarkers and bioanalytical discovery, rare disease diagnostics and bioinformatics, supporting Alexion’s pipeline from target discovery through post-marketing.
Seng was previously Senior Vice President & Chief Scientific Officer of the Rare Disease Research Unit at Pfizer. Prior to Joining Pfizer, he held roles including Group Vice President of Genetic Diseases Science at Genzyme as well as the Global Head of Research of Rare Diseases at Sanofi. He has contributed to the development of several medicines for patients with rare diseases, co-authored over 280 research articles and reviews and is a named co-inventor on sixty-four issued US patents in the area of biotechnology.
Seng obtained his BSc and PhD degrees in Biochemistry at the University of London and trained as a postdoctoral fellow in the field of tumor biology at the National Institute of Medical Research, U.K.